PlainRecalls
FDA Drug Moderate Class II Terminated

DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/mL), 10 mL Single Use Vial, Distributed by: Sun Pharmaceutical Industries , Inc. Cranbury, NJ 08512. Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway. Halol-389 350, Gujarat, India. NDC 47335-049-40

Reported: January 31, 2018 Initiated: January 16, 2018 #D-0229-2018

Product Description

DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/mL), 10 mL Single Use Vial, Distributed by: Sun Pharmaceutical Industries , Inc. Cranbury, NJ 08512. Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway. Halol-389 350, Gujarat, India. NDC 47335-049-40

Reason for Recall

Lack Of Assurance Of Sterility

Details

Units Affected
393 vials
Distribution
Product was distributed nationwide in the USA
Location
Cranbury, NJ

Frequently Asked Questions

What product was recalled?
DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/mL), 10 mL Single Use Vial, Distributed by: Sun Pharmaceutical Industries , Inc. Cranbury, NJ 08512. Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway. Halol-389 350, Gujarat, India. NDC 47335-049-40. Recalled by Sun Pharmaceutical Industries, Inc.. Units affected: 393 vials.
Why was this product recalled?
Lack Of Assurance Of Sterility
Which agency issued this recall?
This recall was issued by the FDA Drug on January 31, 2018. Severity: Moderate. Recall number: D-0229-2018.